Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceu… Read more
Regenerx Biopharm In (RGRX) - Total Assets
Latest total assets as of March 2023: $186.81K USD
Based on the latest financial reports, Regenerx Biopharm In (RGRX) holds total assets worth $186.81K USD as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Regenerx Biopharm In - Total Assets Trend (2000–2022)
This chart illustrates how Regenerx Biopharm In’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Regenerx Biopharm In - Asset Composition Analysis
Current Asset Composition (December 2022)
Regenerx Biopharm In's total assets of $186.81K consist of 80.3% current assets and 19.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2022)
This chart illustrates how Regenerx Biopharm In's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regenerx Biopharm In's current assets represent 80.3% of total assets in 2022, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 76.1% of total assets in 2022, up from 67.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Regenerx Biopharm In Competitors by Total Assets
Key competitors of Regenerx Biopharm In based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Regenerx Biopharm In - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Regenerx Biopharm In generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Regenerx Biopharm In is currently not profitable relative to its asset base.
Regenerx Biopharm In - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 2.33 | 0.94 |
| Quick Ratio | 0.07 | 2.33 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.68 Million | $ 535.54K | $ -47.77K |
Regenerx Biopharm In - Advanced Valuation Insights
This section examines the relationship between Regenerx Biopharm In's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -70.3% |
| Total Assets | $382.18K |
| Market Capitalization | $449.00 USD |
Valuation Analysis
Below Book Valuation: The market values Regenerx Biopharm In's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Regenerx Biopharm In's assets decreased by 70.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Regenerx Biopharm In (2000–2022)
The table below shows the annual total assets of Regenerx Biopharm In from 2000 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $382.18K | -70.26% |
| 2021-12-31 | $1.28 Million | +132.87% |
| 2020-12-31 | $551.79K | -22.48% |
| 2019-12-31 | $711.76K | +153.26% |
| 2018-12-31 | $281.04K | +23.77% |
| 2017-12-31 | $227.07K | -73.67% |
| 2016-12-31 | $862.40K | +140.74% |
| 2015-12-31 | $358.22K | -62.25% |
| 2014-12-31 | $949.00K | +2106.98% |
| 2013-12-31 | $43.00K | -87.96% |
| 2012-12-31 | $357.00K | -7.03% |
| 2011-12-31 | $384.00K | -90.92% |
| 2010-12-31 | $4.23 Million | -7.77% |
| 2009-12-31 | $4.58 Million | -22.61% |
| 2008-12-31 | $5.92 Million | -31.30% |
| 2007-12-31 | $8.62 Million | -50.74% |
| 2006-12-31 | $17.50 Million | +126.56% |
| 2005-12-31 | $7.72 Million | +134.87% |
| 2004-12-31 | $3.29 Million | +196.31% |
| 2003-12-31 | $1.11 Million | +102.93% |
| 2002-12-31 | $547.00K | +341.13% |
| 2001-12-31 | $124.00K | -75.20% |
| 2000-12-31 | $500.00K | -- |